{"filing":{"accession_number":"0001534120-26-000044","cik":"0001534120","ticker":"AVTX","company_name":"Avalo Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-23","report_date":null,"primary_document":"avtx-20260623.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1534120/000153412026000044/avtx-20260623.htm"},"events":[{"id":12973,"run_id":11515,"accession_number":"0001534120-26-000044","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"The filing discloses the appointment of Ron Philip to the Board of Directors of Avalo Therapeutics, effective June 23, 2026. The principal disclosed action is a person taking a role as director and committee member. While the disclosure includes compensatory arrangements (stock option grant of 40,200 shares), the core event is the appointment itself, making exec_appointment the most salient classification. Board appointments by experienced executives (Philip's background includes CEO roles at Spark Therapeutics and Orbital Therapeutics) are material to investors.","company_name":"Avalo Therapeutics, Inc.","ticker":"AVTX","filing_date":"2026-06-23","form":"8-K","submitted_at":null,"items":[{"id":9982,"accession_number":"0001534120-26-000044","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Ron Philip to the Board of Directors of Avalo Therapeutics, effective June 23, 2026. The principal disclosed action is a person taking a role as director and committee member. While the disclosure includes compensatory arrangements (stock option grant of 40,200 shares), the core event is the appointment itself, making exec_appointment the most salient classification. Board appointments by experienced executives (Philip's background includes CEO roles at Spark Therapeutics and Orbital Therapeutics) are material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-23T11:03:36.286214+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":9982,"accession_number":"0001534120-26-000044","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Ron Philip to the Board of Directors of Avalo Therapeutics, effective June 23, 2026. The principal disclosed action is a person taking a role as director and committee member. While the disclosure includes compensatory arrangements (stock option grant of 40,200 shares), the core event is the appointment itself, making exec_appointment the most salient classification. Board appointments by experienced executives (Philip's background includes CEO roles at Spark Therapeutics and Orbital Therapeutics) are material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-23T11:03:36.286214+00:00","company_name":"Avalo Therapeutics, Inc.","ticker":"AVTX","filing_date":"2026-06-23"}]}